Kezhov Biotechnology Co., Ltd
Taiwan新北市汐止區新台五路一段75號17樓之5、75號16樓之13 products representedMar 11, 2013 – Mar 15, 2021
VerifiedTFDA · Taiwan Food and Drug Administration registry
3
Products represented
3
Manufacturers
1
Active products
Mar 2021
Latest registration
Company details
- Address
- 新北市汐止區新台五路一段75號17樓之5、75號16樓之1
- Authorization Code
- 27643054
Regulatory footprint
Search Kezhov Biotechnology Co., Ltd across other regulatory registries
Recent registrations
Latest 5 products represented by this organization
Most popular products
Products with most registrations
Represented manufacturers
Manufacturers whose products are represented by this organization
Recent represented products
Most recent products (showing top 20)
Clovers (HIPEX) non-powered plinth (non-sterile)
Registered: Mar 15, 2021 • Expires: Mar 15, 2026
Cancelled
- Risk Class
- Class 1
- Type
- MD
- Manufacturer
- DAEYANG MEDICAL Co., Ltd
"Elisser" Disser coronary artery coating stent system
Registered: Nov 03, 2015 • Expires: Nov 03, 2025
- Risk Class
- Class 3
- Manufacturer
- VistaMed Limited;; Elixir Medical Corporation
"Niichimori Tokuri" manual instrument for general surgery (not sterilized)
Registered: Mar 11, 2013 • Expires: Mar 11, 2018
Cancelled
- Risk Class
- Class 1
- Manufacturer
- 21 CENTURY MEDICAL CO., LTD.
About this profile
Explore comprehensive authorized representative profile for Kezhov Biotechnology Co., Ltd through Pure Global AI's free Taiwan medical device database. This authorized representative handles 3 product registrations across 3 manufacturers and 3 unique product types. Their regulatory history spans from Mar 11, 2013 to Mar 15, 2021.
This page provides detailed insights including 3 recent product registrations, 3 most popular products with Clovers (HIPEX) non-powered plinth (non-sterile) having 1 registrations, and 3 represented manufacturers including DAEYANG MEDICAL Co., Ltd. Pure Global AI offers free access to Taiwan's medical device database, enabling global MedTech companies to analyze market dynamics and identify opportunities.